Cargando…
A129 CYP2C19 PHARMACOGENETIC TESTING IN PAEDIATRIC PATIENTS WITH EOSINOPHILIC ESOPHAGITIS INFLUENCES DOSING OF PROTON-PUMP-INHIBITORS AND RESPONSE TO THERAPY
BACKGROUND: Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder that can be treated with a proton pump inhibitor (PPI). Pharmacogenetics (PGx) is the study of how variations in an individual’s genome influences drug response. Genetic variation in the metabolism gene CYP2C19 can produce...
Autores principales: | Bortolin, K A, Cohn, I, Da Silva, S, Ito, S, Marcon, P, Afzal, N, Scodellaro, S, Verstegen, R, Hulst, J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859342/ http://dx.doi.org/10.1093/jcag/gwab049.128 |
Ejemplares similares
-
A128 PATIENT CHARACTERIZATION AND ASSESSMENT OF REMISSION RATES IN CHILDREN WITH EOSINOPHILIC ESOPHAGITIS AFTER INITIAL TREATMENT AND 1-YEAR POST-DIAGNOSIS
por: Da Silva, S, et al.
Publicado: (2022) -
A130 LONGITUDINAL GROWTH OF PREESCHOOLERS WITH EOSINOPHILIC ESOPHAGITIS
por: Carrión-Jaramillo, E, et al.
Publicado: (2022) -
Eosinophilic Esophagitis on and off Proton Pump Inhibitor
por: Zimmer, Vincent, et al.
Publicado: (2023) -
Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine
por: El Rouby, Nihal, et al.
Publicado: (2018) -
A163 EVALUATING THE ASSOCIATION BETWEEN PERIPHERAL BLOOD EOSINOPHILS AND DRUG RESPONSE IN CROHN’S DISEASE: A PRELIMINARY REPORT
por: Cai, B, et al.
Publicado: (2022)